Silence Therapeutics discloses separation agreement with former executive Craig Tooman

Silence Therapeutics plc

Salary continuation of $655,000 for 12 months plus lump sum cash severance of $250,000.
Bonus payment of $283,746.03 and healthcare premium reimbursement of $46,896.48.
Extended option exercise period: 24 months for 2023 Plan options, 12 months for 2018 Plan options.
Acceleration of unvested options upon change of control within 12 months post-separation.
Confidentiality, non-disparagement, non-solicitation covenants and release of claims.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Craig Tooman

Other Named Officer

SLN · Silence Therapeutics plc

Effective: 2025-12-14
Filed: July 16, 2026, 5:20 PM ET

As reported in the Original Form 8-K, effective as of December 14, 2025 (the “Separation Date”), Craig Tooman agreed by mutual consent to end his employment with Silence Therapeutics plc (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Craig Tooman resigned as other_named_officer at Silence Therapeutics plc.

Action: resigned

Exact text from the filing

As reported in the Original Form 8-K, effective as of December 14, 2025 (the “Separation Date”), Craig Tooman agreed by mutual consent to end his employment with Silence Therapeutics plc (the “Company”).

View on SEC.gov

Silence Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001193125-26-306251

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.